-
公开(公告)号：US20180127459A1
公开(公告)日：2018-05-10
申请号：US15564224
申请日：2016-04-04
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor： Martin Hall , Mikael Berg , Ida Eklind , Sandeep Kristiansson
IPC: C07K1/18 , C07K14/755 , A61P7/00 , B01D15/36
CPC classification number: C07K1/18 , A61K38/00 , A61P7/00 , B01D15/363 , C07K14/755
Abstract: The present invention relates to the field of chromatography. More closely, the invention relates to a chromatographic method for purification of Factor VIII and von Willebrand factor from a cryoprecipitate of plasma. The chromatographic method is performed on a matrix comprising an inner porous core and outer porous lid surrounding said core.
-
72.发明申请公开(公告)号：US20170259244A1
公开(公告)日：2017-09-14
申请号：US15603285
申请日：2017-05-23
Applicant: GE Healthcare BioProcess R&D AB
Inventor： Martin Hall , Sture Larsson , Andreas Muranyi , Gustav Rodrigo , Jinyu Zou , Per-Mikael Aberg
IPC: B01J20/24 , C07K14/31 , C07K17/10 , B01D15/38 , B01J20/28 , B01J20/285 , B01J20/289 , B01J20/32 , C07K1/22 , C07K16/00
CPC classification number: B01J20/24 , B01D15/3809 , B01J20/28019 , B01J20/285 , B01J20/286 , B01J20/289 , B01J20/3212 , B01J20/3219 , B01J20/3274 , B01J20/3293 , B01J2220/52 , B01J2220/54 , C07K1/22 , C07K14/31 , C07K16/00 , C07K17/00 , C07K17/10 , C07K2317/55
Abstract: The present invention relates to a chromatography ligand, which comprises Domain C from Staphylococcus protein A (SpA), or a functional fragment or variant thereof. The chromatography ligand presents an advantageous capability of withstanding harsh cleaning in place (CIF) conditions, and is capable of binding Fab fragments of antibodies. The ligand may be provided with a terminal coupling group, such as arginine or cysteine, to facilitate its coupling to an insoluble carrier such as beads or a membrane. The invention also relates process of using the ligand in isolation of antibodies, and to a purification protocol which may include washing steps and/or regeneration with alkali.
-
公开(公告)号：US09657055B2
公开(公告)日：2017-05-23
申请号：US14358821
申请日：2012-11-28
Applicant: GE Healthcare BioProcess R&D AB
Inventor： Hans J. Johansson , Ronnie Palmgren
IPC: B01D15/38 , C07K1/22 , C07K14/31 , C07K19/00 , B01J20/286 , B01J20/32 , C07K14/245 , B01D15/34
CPC classification number: C07K1/22 , B01D15/34 , B01D15/3809 , B01J20/285 , B01J20/286 , B01J20/289 , B01J20/3274 , C07K14/245 , C07K14/31 , C07K2319/00
Abstract: The invention discloses a polypeptide capable of binding immunoglobulins or immunoglobulin-containing proteins, which polypeptide comprises six or more domains of protein Z or the C domain of protein A or a functional variant thereof. It also discloses separation matrices comprising the polypeptide and methods of using the separation matrices for separation of immunoglobulins or immunoglobulin-containing proteins.
-
公开(公告)号：US20170067031A1
公开(公告)日：2017-03-09
申请号：US15355675
申请日：2016-11-18
Applicant: GE Healthcare BioProcess R&D AB
Inventor： Patrik Adielsson , Tobias E. Soderman , Anna Akerblom
CPC classification number: C12N7/00 , B01D15/3847 , C12N2760/16151
Abstract: The present invention relates to a method for endotoxin removal from a sample comprising the following steps: combining the sample comprising one or more target molecule(s) with a chromatography media comprising beads having an inner porous core functionalized with ligands capable of binding endotoxin and an outer porous layer without functional groups and a pore size small enough to exclude the target molecule from the inner core; and collecting the sample from the media, wherein the sample comprises an endotoxin level which is at least 75% less, preferably 90% less, than before the removal and the yield of the target molecule is at least 75%.
Abstract translation: 本发明涉及一种从样品中去除内毒素的方法，包括以下步骤：将包含一种或多种靶分子的样品与包含珠的色谱介质组合，所述珠粒具有由能够结合内毒素的配体功能化的内部多孔核心和 没有官能团的外部多孔层和足够小以从靶芯排出靶分子的孔径; 并从培养基中收集样品，其中样品包含与去除前相比至少75％以上，优选90％以下的内毒素水平，并且目标分子的产率为至少75％。
-
公开(公告)号：US20170056877A1
公开(公告)日：2017-03-02
申请号：US15292093
申请日：2016-10-12
Applicant: GE Healthcare BioProcess R&D AB
Inventor： Karol Lacki
CPC classification number: B01L3/50255 , B01L3/5085 , B01L2300/069 , G01N30/466 , G01N30/6043 , G01N30/8658 , Y10T436/25
Abstract: A micro titre plate comprising a number of wells filled with separation matrix. According to the invention the volume of the separation matrix is varied between at least some of the wells.
Abstract translation: 包含多个填充有分离基质的孔的微量滴定板。 根据本发明，分离基质的体积在至少一些孔之间变化。
-
Patent Agency Ranking
公开(公告)号：US20160298065A1
公开(公告)日：2016-10-13
申请号：US15037539
申请日：2014-11-26
Applicant: GE Healthcare BioProcess R&D AB
Inventor： Jean-Luc Maloisel , Tobias Soderman , Ola Lind
IPC: C12H1/056 , B01J20/32 , B01J20/28 , C08F251/00
CPC classification number: C12H1/0424 , B01D15/00 , B01J20/28004 , B01J20/321 , B01J20/3212 , B01J20/3219 , B01J20/327 , B01J20/3278 , B01J20/3293 , B01J2220/58 , C08F251/00
Abstract: The invention discloses a separation matrix with a porous solid support and a plurality of polyvinylpyrrolidone (PVP) polymer chains covalently attached to the solid support. The polyvinylpyrrolidone polymer chains are either vinylpyrrolidone homopolymer chains or copolymer chains which comprise at least 70 mol % vinylpyrrolidone monomer residues and less than 2 mol % negatively charged monomer residues.
Abstract translation: 本发明公开了具有多孔固体支持物和共价连接到固体支持物上的多个聚乙烯吡咯烷酮（PVP）聚合物链的分离基质。 聚乙烯吡咯烷酮聚合物链是乙烯基吡咯烷酮均聚物链或包含至少70mol％乙烯基吡咯烷酮单体残基和小于2mol％带负电荷的单体残基的共聚物链。
-
公开(公告)号：US20200299325A1
公开(公告)日：2020-09-24
申请号：US16095753
申请日：2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor： Annika Forss , Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
IPC: C07K1/22 , C07K16/00 , C07K14/31 , B01J20/32 , B01J20/26 , B01J20/285 , B01J20/286 , C07K16/12 , C07K17/10
Abstract: The present invention concerns a method of cleaning and/or sanitizing a separation matrix comprising multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support. The method comprises the steps of: a) optionally purifying a mixture comprising a first immunoglobulin using the separation matrix; b) providing a cleaning liquid comprising at least 50% by volume of an aqueous alkali metal hydroxide solution; and c) cleaning and/or sanitizing the separation matrix by contacting the cleaning liquid with the separation matrix for a predetermined contact time. The alkali-stabilized Protein A domains comprise mutants of a parental Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO 51 or SEQ ID NO 52, wherein the amino acid residues at positions 13 and 44 of SEQ ID NO 51 or 52 are asparagines and wherein at least the asparagine residue at position 3 of SEQ ID NO 51 or 52 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
-
公开(公告)号：US10730908B2
公开(公告)日：2020-08-04
申请号：US15798784
申请日：2017-10-31
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor： Annika Forss , Mats Ander , Tomas Bjorkman , Hans Blom , Jesper Hansson , Gustav Rodrigo
IPC: C07K1/16 , B01D15/08 , C07K1/22 , C07K16/00 , B01J20/286 , B01J20/285 , B01D15/18 , B01D15/34 , C07K14/31
Abstract: The invention relates to a method of isolating an immunoglobulin, comprising the steps of: a) providing a separation matrix comprising at least 15 mg/ml multimers of immunoglobulin-binding alkali-stabilized Protein A domains covalently coupled to a porous support, wherein the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml; b) contacting a liquid sample comprising an immunoglobulin with the separation matrix; c) washing the separation matrix with a washing liquid; d) eluting the immunoglobulin from the separation matrix with an elution liquid; and e) cleaning the separation matrix with a cleaning liquid comprising at least 0.5 M NaOH.
-
公开(公告)号：US20190218265A1
公开(公告)日：2019-07-18
申请号：US16328058
申请日：2017-09-05
Applicant: GE Healthcare BioProcess R&D AB
Inventor： Sophia Hober , Sara Kanje , Johan Nilvebrant
CPC classification number: C07K14/4728 , C07K1/22 , C07K14/31 , C07K2319/20 , C07K2319/30 , C07K2319/705
Abstract: The present invention is within the field of protein engineering and purification. The invention relates to a target-binding polypeptide mutant of an IgG binding polypeptide, such as Protein A, Protein G, Protein L or Protein M, comprising a metal binding motif. More closely the invention relates to an Fc binding ligand comprising an engineered protein based on the Protein A derived Z domain, to which a calcium binding EF-loop has been introduced.
-
公开(公告)号：US20190119318A1
公开(公告)日：2019-04-25
申请号：US16096952
申请日：2017-05-10
Applicant: GE HEALTHCARE BIOPROCESS R&D AB
Inventor： Gustav José Rodrigo , Tomas Bjorkman , Mats Ander , Jesper Ulf Hansson
Abstract: The invention relates to a separation matrix comprising at least 11 mg/ml Fc-binding ligands covalently coupled to a porous support, wherein: a) the ligands comprise multimers of alkali-stabilized Protein A domains, and b) the porous support comprises cross-linked polymer particles having a volume-weighted median diameter (d50,v) of 56-70 micrometers and a dry solids weight of 55-80 mg/ml.
-
-
-
-
-
-
-
-
-
Search Results
92
records
(took 0.031 seconds)
